文献速递血栓与止血

小鼠癌症模型中代谢物通过芳香烃受体-组织因子轴增强静脉血栓形成

Metabolites in a mouse cancer model enhance venous thrombogenicity through the aryl hydrocarbon receptor-tissue factor axis.
PubMed 文献 · Blood · 2019-01-01

该研究在结肠癌特异性静脉血栓栓塞(VTE)小鼠模型中,发现异种移植小鼠血浆犬尿氨酸和硫酸吲哚酚升高且与下腔静脉血栓重量正相关,这些代谢物通过激活芳香烃受体(AHR)上调内皮组织因子(TF)和纤溶酶原激活物抑制剂1(PAI-1),药理学抑制AHR可减少血栓重量。

要点

  • 癌症小鼠血浆中色氨酸代谢物犬尿氨酸和硫酸吲哚酚升高,与下腔静脉血栓重量正相关
  • 这些代谢物通过AHR依赖方式激活内皮细胞,上调TF和PAI-1表达
  • 药理学抑制AHR可抑制内皮TF和PAI-1表达并减少血栓重量

核心结论

  • 癌症小鼠模型中色氨酸代谢物失调,通过AHR-TF/PAI-1轴增强静脉血栓形成。

研究设计与样本

  • 研究采用结肠癌特异性VTE小鼠模型(下腔静脉结扎模型),比较异种移植小鼠与对照小鼠。
  • 对小鼠血浆进行靶向代谢组学分析,检测有促血栓倾向的代谢物。

主要发现

  • 注射人结肠腺癌细胞的裸鼠下腔静脉血栓重量显著高于对照小鼠。
  • 异种移植小鼠血浆中犬尿氨酸和硫酸吲哚酚水平升高,且与下腔静脉血栓大小正相关。
  • 异种移植小鼠血浆以AHR依赖方式激活AHR通路,并增加静脉内皮细胞TF和PAI-1水平。
  • 异种移植小鼠下腔静脉内皮显示核AHR及TF、PAI-1表达上调。
  • 药理学抑制AHR活性可抑制下腔静脉内皮细胞TF和PAI-1表达,并减少犬尿氨酸注射和异种移植小鼠的血栓重量。

临床怎么用

  • 在癌症相关VTE中,可考虑检测色氨酸代谢物(犬尿氨酸、硫酸吲哚酚)水平以评估血栓风险。
  • AHR-TF/PAI-1轴可能成为癌症相关VTE的潜在治疗靶点。

局限性

  • 研究仅基于小鼠模型,结论尚未在人体中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with malignancy are at 4- to 7-fold higher risk of venous thromboembolism (VTE), a potentially fatal, yet preventable complication. Although general mechanisms of thrombosis are enhanced in these patients, malignancy-specific triggers and their therapeutic implication remain poorly understood. Here we examined a colon cancer-specific VTE model and probed a set of metabolites with prothrombotic propensity in the inferior vena cava (IVC) ligation model. Athymic mice injected with human colon adenocarcinoma cells exhibited significantly higher IVC clot weights, a biological readout of venous thrombogenicity, compared with the control mice. Targeted metabolomics analysis of plasma of mice revealed an increase in the blood levels of kynurenine and indoxyl sulfate (tryptophan metabolites) in xenograft-bearing mice, which correlated positively with the increase in the IVC clot size. These metabolites are ligands of aryl hydrocarbon receptor (AHR) signaling. Accordingly, plasma from the xenograft-bearing mice activated the AHR pathway and augmented tissue factor (TF) and plasminogen activator inhibitor 1 (PAI-1) levels in venous endothelial cells in an AHR-dependent manner. Consistent with these findings, the endothelium from the IVC of xenograft-bearing animals revealed nuclear AHR and upregulated TF and PAI-1 expression, telltale signs of an activated AHR-TF/PAI-1 axis. Importantly, pharmacological inhibition of AHR activity suppressed TF and PAI-1 expression in endothelial cells of the IVC and reduced clot weights in both kynurenine-injected and xenograft-bearing mice. Together, these data show dysregulated tryptophan metabolites in a mouse cancer model, and they reveal a novel link between these metabolites and the control of the AHR-TF/PAI-1 axis and VTE in cancer.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Belghasem M, Roth D, Richards S, et al. Metabolites in a mouse cancer model enhance venous thrombogenicity through the aryl hydrocarbon receptor-tissue factor axis. Blood. 2019. PMID: 31877217. doi:10.1182/blood.2019001675

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。